AKT1 and non-small cell lung carcinoma: PI3K/AKT is over-activated in NSCLC cells [9], and overexpression of AKT1 leads to cisplatin resistance in lung cancer cells, while inhibition of AKT1 expression can reverse multi-drug resistant lung adenocarcinoma cell (A549/CDDP) resistance to cisplatin.